Format

Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2019 May 7. pii: cebp.1194.2018. doi: 10.1158/1055-9965.EPI-18-1194. [Epub ahead of print]

Use of statin medications following diagnosis in relation to survival among women with ovarian cancer.

Author information

1
Department of Epidemiology, School of Public Health, University of Washington hardingb@uw.edu.
2
Department of Epidemiology, School of Public Health, University of Washington.
3
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington.

Abstract

BACKGROUND:

It has been suggested that the likelihood of survival among women with ovarian cancer could be increased by post-diagnosis statin use. This study examines the potential association between post-diagnosis statin use and cancer-specific mortality among women with ovarian cancer.

METHODS:

This cohort study used SEER-Medicare data on women 66+ years of age diagnosed with ovarian cancer during 2007-2012 who were enrolled in Medicare parts A, B and D during the year after diagnosis. Statin use was defined as two or more fills for a statin during the year after diagnosis. Ovarian cancer-specific death was assessed starting one year after diagnosis. Marginal structural Cox models were used, adjusting for the inverse probability of treatment weighting and censoring weighting. Treatment weights and censoring weights were calculated using logistic regression models with a priori defined covariates.

RESULTS:

Among 2,195 women with ovarian cancer, 489 (22%) used statins within one year after their diagnosis. Over a mean follow-up of 2.2 years, 796 (36%) women died from ovarian cancer. The adjusted hazard ratio (aHR) for ovarian cancer mortality comparing statin users to non-users was 0.74 (95% CI 0.60-0.91).

CONCLUSIONS:

Findings from this and prior work suggest statin use following a diagnosis with ovarian cancer is associated with a lower risk of cancer death.

IMPACT:

Because, in most women, statin administration has limited side effects, a randomized trial of statins among ovarian cancer patients may be warranted.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center